Novo Nordisk CEO defends high price off Ozempic and Wegovy

Ozempic CEO grilled on Capitol Hill over high cost of popular weight loss drugПодробнее

NBC News Exclusive: Ozempic and Wegovy Novo Nordisk CEO speaks out on high prices, drug shortagesПодробнее

Ozempic and Wegovy drugmaker CEO defends high costs of drugsПодробнее

Novo Nordisk CEO on Catalent, Ozempic and WegovyПодробнее

CEO of Novo Nordisk grilled on Ozempic prices in U.S.Подробнее

Wegovy, Ozempic maker to face off on Capitol Hill over high pricesПодробнее

Why Ozempic, Wegovy costs are higher in U.S. vs. other nationsПодробнее

Novo Nordisk CEO Lars Fruergaard Jørgensen on Q4 results, Wegovy demand and drug pipeline outlookПодробнее

How Ozempic And Wegovy Accidentally Made Novo Nordisk A $400B CompanyПодробнее

The CEO Behind Ozempic, Wegovy and Europe's Most Valuable CompanyПодробнее

The Novo Nordisk scientist behind Ozempic, Wegovy weight loss researchПодробнее

CEO of Novo Nordisk grilled over weight loss drugs' high priceПодробнее

40,000 Preventable Deaths: The High Cost of Life-Saving Ozempic and WegovyПодробнее

Maker of popular diabetes and weight-loss drugs grilled about high cost in the U.S.Подробнее

Weight-loss drugmaker CEO faces questions over high costsПодробнее

Novo Nordisk must lower the cost of OzempicПодробнее

Ozempic, Wegovy Really Good Value: Novo Nordisk CEOПодробнее

CEO of Ozempic and Wegovy questioned over drug's high prices in U.S. over other countriesПодробнее

Novo Nordisk CEO on safety concerns associated with off-label use of diabetes drugsПодробнее